Tia L. Bush Sells 17,813 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Tia L. Bush sold 17,813 shares of the stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $18.00, for a total transaction of $320,634.00. Following the completion of the transaction, the chief technology officer now directly owns 147,615 shares of the company’s stock, valued at $2,657,070. This trade represents a 10.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Centessa Pharmaceuticals Trading Up 5.1 %

NASDAQ CNTA traded up $0.85 during trading hours on Tuesday, hitting $17.60. The company’s stock had a trading volume of 816,790 shares, compared to its average volume of 431,601. The stock has a fifty day moving average of $16.53 and a 200 day moving average of $13.40. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a twelve month low of $6.65 and a twelve month high of $18.97. The firm has a market capitalization of $2.32 billion, a P/E ratio of -11.50 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. First Light Asset Management LLC boosted its position in shares of Centessa Pharmaceuticals by 59.2% during the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock worth $43,168,000 after purchasing an additional 1,778,515 shares in the last quarter. Farallon Capital Management LLC raised its stake in Centessa Pharmaceuticals by 438.0% during the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock worth $18,024,000 after buying an additional 1,625,000 shares during the period. Janus Henderson Group PLC bought a new position in Centessa Pharmaceuticals during the third quarter worth about $20,698,000. Franklin Resources Inc. lifted its holdings in Centessa Pharmaceuticals by 99.1% during the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after acquiring an additional 1,145,823 shares in the last quarter. Finally, Driehaus Capital Management LLC grew its stake in Centessa Pharmaceuticals by 89.5% in the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after acquiring an additional 987,997 shares during the period. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Jefferies Financial Group increased their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. BMO Capital Markets increased their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target for the company. Finally, Guggenheim boosted their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.